Completed
Efficacy of Intralesional Vitamin D Injection for Treatment of Common Warts: A Randomized Controlled Trial
What is being tested
Vitamin D3
+ Placebo
Drug
Who is being recruted
DNA Virus Infections+7
+ Infections
+ Skin Diseases
Over 18 Years
+13 Eligibility Criteria
How is the trial designed
Treatment Study
Placebo-ControlledPhase 2
Interventional
Study Start: October 2020
Summary
Principal SponsorStephen P. Merry
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: October 20, 2020
Actual date on which the first participant was enrolled.Researchers are trying to find out if injecting Vitamin D into a wart is an effective treatment.
Official TitleEfficacy of Intralesional Vitamin D Injection for Treatment of Common Warts: A Randomized Controlled Trial
Principal SponsorStephen P. Merry
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
77 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
DNA Virus InfectionsInfectionsSkin DiseasesSkin Diseases, InfectiousTumor Virus InfectionsVirus DiseasesWartsSkin Diseases, ViralSkin and Connective Tissue DiseasesPapillomavirus Infections
Criteria
4 inclusion criteria required to participate
Adult patients seen at the Mayo Clinic Rochester practices
Patients suffering from one or more cutaneous warts as diagnosed by the examining physician at baseline visit on typical diagnostic characteristics
Able to provide consent
Both recalcitrant and non-recalcitrant warts will be included
9 exclusion criteria prevent from participating
Patients with prior use of home or office-based destructive treatments for this wart(s) in the last 1 month with salicylic acid (SA) or cryotherapy
Immunoadjuvant therapy for warts in the last 4 months (e.g Candida)
History of vitamin D injection of warts ever
High-dose vitamin D supplementation (>4,000 IU daily or equivalent) in the preceding 3 months
Show More Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
2 intervention groups are designated in this study
50% chance of being blinded to the placebo group
Treatment Groups
Group I
ExperimentalSubjects will receive a Vitamin D3 injection into their wart
Group II
PlaceboSubjects will receive a placebo injection into their wart
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Suspended
CompletedOne Study Center